CT 2584
Alternative Names: Apra; CT-2584; CT-2584 mesylateLatest Information Update: 30 Oct 2020
Price :
$50 *
At a glance
- Originator Cell Therapeutics
- Developer CTI BioPharma; Shire Pharmaceuticals Group
- Class
- Mechanism of Action Angiogenesis inhibitors; Lysophosphatidic acid acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Ovarian cancer; Prostate cancer; Sarcoma
Most Recent Events
- 19 Oct 2020 CTI BioPharma terminates a phase II trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater) in USA, prior to October 2020 (NCT00004026)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 31 Dec 2001 Discontinued - Phase-II for Cancer in Canada (IV-infusion)